Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program and professor of medicine at the Icahn School of Medicine, Mount Sinai Hospital, discusses the current treatment landscape for liver cancer and the advances seen over the last decade at the 2018 International Liver Cancer Association Annual Conference.
In the last 12 years, Llovet says that there was only 1 effective drug, sorafenib (Nexavar) available for this patient population. There were many negative trials over the last several years looking for additional treatment options, until more recently.
Llovet says there has been a revolution in the treatment landscape of liver cancer. Three drugs are now available in the second-line setting, including regorafenib (Stivarga), cabozantinib (Cabometyx), and ramucirumab (Cyramza). In the frontline, lenvatinib (Lenvima) has also proven to be similar to sorafenib in trials with noninferiority design.
Moving forward, Llovet says the question to be answered is where are we going next? What will be the next steps in this treatment paradigm?
For more resources and information regarding ILCA: http://targetedonc.com/partners/ILCA